Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy

Ying Zhou, Mrinmoy Maiti, Amit Sharma, Miae Won, Le Yu, Lan Xi Miao, Jinwoo Shin, Arup Podder, Kondapa Naidu Bobba, Jiyou Han, Sankarprasad Bhuniya, Jong Seung Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38 (irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific activation and therapy. The theranostic AzP1 was found to be stable within a biologically relevant pH scale and was chemically inert towards other competitive biological analytes. However, upon treatment with rat-liver microsomes, AzP1 showed a self-calibrated fluorescence enhancement at λem = 560 nm. The cytotoxicity profile of AzP1 was tested in various cancer lines. Under hypoxic conditions, prodrug AzP1 exhibited activation to release the parent drug (SN-38) and enhanced cytotoxicity in cancer cells with concomitant fluorescence enhancement at 560 nm, which served to monitor both the drug activation and tracing purposes. The therapeutic potential of AzP1 for both tumor-specific activation and suppression of tumor weights was validated in xenograft mouse model. Collectively, the synthetic ease and hypoxia-sensitive activation along with promising therapeutic properties highlight the potential of theranostic AzPI in future cancer treatment programs.

Original languageEnglish
Pages (from-to)14-22
Number of pages9
JournalJournal of Controlled Release
Volume288
DOIs
Publication statusPublished - 2018 Oct 28

Fingerprint

irinotecan
Neoplasms
Fluorescence
Therapeutics
Prodrugs
Liver Microsomes
Tumor Burden
Heterografts
Antineoplastic Agents
Hypoxia
Theranostic Nanomedicine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy. / Zhou, Ying; Maiti, Mrinmoy; Sharma, Amit; Won, Miae; Yu, Le; Miao, Lan Xi; Shin, Jinwoo; Podder, Arup; Bobba, Kondapa Naidu; Han, Jiyou; Bhuniya, Sankarprasad; Kim, Jong Seung.

In: Journal of Controlled Release, Vol. 288, 28.10.2018, p. 14-22.

Research output: Contribution to journalArticle

Zhou, Y, Maiti, M, Sharma, A, Won, M, Yu, L, Miao, LX, Shin, J, Podder, A, Bobba, KN, Han, J, Bhuniya, S & Kim, JS 2018, 'Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy', Journal of Controlled Release, vol. 288, pp. 14-22. https://doi.org/10.1016/j.jconrel.2018.08.036
Zhou, Ying ; Maiti, Mrinmoy ; Sharma, Amit ; Won, Miae ; Yu, Le ; Miao, Lan Xi ; Shin, Jinwoo ; Podder, Arup ; Bobba, Kondapa Naidu ; Han, Jiyou ; Bhuniya, Sankarprasad ; Kim, Jong Seung. / Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy. In: Journal of Controlled Release. 2018 ; Vol. 288. pp. 14-22.
@article{1da327ed31be40e2969ea7d0799e1b4b,
title = "Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy",
abstract = "We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38 (irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific activation and therapy. The theranostic AzP1 was found to be stable within a biologically relevant pH scale and was chemically inert towards other competitive biological analytes. However, upon treatment with rat-liver microsomes, AzP1 showed a self-calibrated fluorescence enhancement at λem = 560 nm. The cytotoxicity profile of AzP1 was tested in various cancer lines. Under hypoxic conditions, prodrug AzP1 exhibited activation to release the parent drug (SN-38) and enhanced cytotoxicity in cancer cells with concomitant fluorescence enhancement at 560 nm, which served to monitor both the drug activation and tracing purposes. The therapeutic potential of AzP1 for both tumor-specific activation and suppression of tumor weights was validated in xenograft mouse model. Collectively, the synthetic ease and hypoxia-sensitive activation along with promising therapeutic properties highlight the potential of theranostic AzPI in future cancer treatment programs.",
author = "Ying Zhou and Mrinmoy Maiti and Amit Sharma and Miae Won and Le Yu and Miao, {Lan Xi} and Jinwoo Shin and Arup Podder and Bobba, {Kondapa Naidu} and Jiyou Han and Sankarprasad Bhuniya and Kim, {Jong Seung}",
year = "2018",
month = "10",
day = "28",
doi = "10.1016/j.jconrel.2018.08.036",
language = "English",
volume = "288",
pages = "14--22",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy

AU - Zhou, Ying

AU - Maiti, Mrinmoy

AU - Sharma, Amit

AU - Won, Miae

AU - Yu, Le

AU - Miao, Lan Xi

AU - Shin, Jinwoo

AU - Podder, Arup

AU - Bobba, Kondapa Naidu

AU - Han, Jiyou

AU - Bhuniya, Sankarprasad

AU - Kim, Jong Seung

PY - 2018/10/28

Y1 - 2018/10/28

N2 - We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38 (irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific activation and therapy. The theranostic AzP1 was found to be stable within a biologically relevant pH scale and was chemically inert towards other competitive biological analytes. However, upon treatment with rat-liver microsomes, AzP1 showed a self-calibrated fluorescence enhancement at λem = 560 nm. The cytotoxicity profile of AzP1 was tested in various cancer lines. Under hypoxic conditions, prodrug AzP1 exhibited activation to release the parent drug (SN-38) and enhanced cytotoxicity in cancer cells with concomitant fluorescence enhancement at 560 nm, which served to monitor both the drug activation and tracing purposes. The therapeutic potential of AzP1 for both tumor-specific activation and suppression of tumor weights was validated in xenograft mouse model. Collectively, the synthetic ease and hypoxia-sensitive activation along with promising therapeutic properties highlight the potential of theranostic AzPI in future cancer treatment programs.

AB - We report herein, an azo-derivative (AzP1) of FDA approved antineoplastic drug SN-38 (irinotecan analogue) as a theranostic agent with a potential for both tumor hypoxia-specific activation and therapy. The theranostic AzP1 was found to be stable within a biologically relevant pH scale and was chemically inert towards other competitive biological analytes. However, upon treatment with rat-liver microsomes, AzP1 showed a self-calibrated fluorescence enhancement at λem = 560 nm. The cytotoxicity profile of AzP1 was tested in various cancer lines. Under hypoxic conditions, prodrug AzP1 exhibited activation to release the parent drug (SN-38) and enhanced cytotoxicity in cancer cells with concomitant fluorescence enhancement at 560 nm, which served to monitor both the drug activation and tracing purposes. The therapeutic potential of AzP1 for both tumor-specific activation and suppression of tumor weights was validated in xenograft mouse model. Collectively, the synthetic ease and hypoxia-sensitive activation along with promising therapeutic properties highlight the potential of theranostic AzPI in future cancer treatment programs.

UR - http://www.scopus.com/inward/record.url?scp=85052658395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052658395&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.08.036

DO - 10.1016/j.jconrel.2018.08.036

M3 - Article

C2 - 30170068

AN - SCOPUS:85052658395

VL - 288

SP - 14

EP - 22

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -